PLRX - Pliant Therapeutics Inc

1.39
0.070   5.036%

Share volume: 654,678
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$1.32
0.07
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 23%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.51%
1 Month
20.87%
3 Months
5.30%
6 Months
-15.76%
1 Year
-11.18%
2 Year
-90.43%
Key data
Stock price
$1.39
P/E Ratio 
0.00
DAY RANGE
$1.29 - $1.40
EPS 
-$3.09
52 WEEK RANGE
$1.09 - $1.95
52 WEEK CHANGE
-$12.03
MARKET CAP 
90.854 M
YIELD 
N/A
SHARES OUTSTANDING 
61.449 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
0.97
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$391,803
AVERAGE 30 VOLUME 
$648,312
Company detail
CEO: Bernard Coulie
Region: US
Website: pliantrx.com
Employees: 90
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pliant Therapeutics, Inc. discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins.

Recent news